4//SEC Filing
Vivo Capital VIII, LLC 4
Accession 0001567619-20-018010
CIK 0001799448other
Filed
Oct 19, 8:00 PM ET
Accepted
Oct 20, 4:59 PM ET
Size
33.9 KB
Accession
0001567619-20-018010
Insider Transaction Report
Form 4
Vivo Capital VIII, LLC
10% Owner
Transactions
- Purchase
Common Stock
2020-10-20$15.00/sh+483,267$7,249,005→ 3,116,658 total(indirect: Vivo Capital Fund VIII, L.P.) - Purchase
Common Stock
2020-10-20$15.00/sh+66,733$1,000,995→ 430,372 total(indirect: Vivo Capital Surplus Fund VIII, L.P.) - Conversion
Series B-2 Preferred Stock
2020-10-20−224,054→ 0 total(indirect: Vivo Capital Fund VIII, L.P.)→ Common Stock (224,054 underlying) - Conversion
Common Stock
2020-10-20+1,885,611→ 1,885,611 total(indirect: Vivo Capital Fund VIII, L.P.) - Conversion
Common Stock
2020-10-20+260,380→ 260,380 total(indirect: Vivo Capital Surplus Fund VIII, L.P.) - Conversion
Common Stock
2020-10-20+30,939→ 363,639 total(indirect: Vivo Capital Surplus Fund VIII, L.P.) - Conversion
Series A Preferred Stock
2020-10-20−1,885,611→ 0 total(indirect: Vivo Capital Fund VIII, L.P.)→ Common Stock (1,885,611 underlying) - Conversion
Series B-1 Preferred Stock
2020-10-20−72,320→ 0 total(indirect: Vivo Capital Surplus Fund VIII, L.P.)→ Common Stock (72,320 underlying) - Conversion
Series A Preferred Stock
2020-10-20−260,380→ 0 total(indirect: Vivo Capital Surplus Fund VIII, L.P.)→ Common Stock (260,380 underlying) - Conversion
Series B-1 Preferred Stock
2020-10-20−523,726→ 0 total(indirect: Vivo Capital Fund VIII, L.P.)→ Common Stock (523,726 underlying) - Conversion
Series B-2 Preferred Stock
2020-10-20−30,939→ 0 total(indirect: Vivo Capital Surplus Fund VIII, L.P.)→ Common Stock (30,939 underlying) - Conversion
Common Stock
2020-10-20+224,054→ 2,633,391 total(indirect: Vivo Capital Fund VIII, L.P.) - Conversion
Common Stock
2020-10-20+523,726→ 2,409,337 total(indirect: Vivo Capital Fund VIII, L.P.) - Conversion
Common Stock
2020-10-20+72,320→ 332,700 total(indirect: Vivo Capital Surplus Fund VIII, L.P.)
Footnotes (2)
- [F1]Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.
- [F2]Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of each of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., the record holder of the securities. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed ad admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
Documents
Issuer
Aligos Therapeutics, Inc.
CIK 0001799448
Entity typeother
Related Parties
1- filerCIK 0001618789
Filing Metadata
- Form type
- 4
- Filed
- Oct 19, 8:00 PM ET
- Accepted
- Oct 20, 4:59 PM ET
- Size
- 33.9 KB